A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.

ABSTRACT: Hemophilia B patients suffer from an inherited blood-clotting defect and require regular administration of blood-clotting factor IX replacement therapy. Recombinant human factor IX produced in cultured CHO cells is nearly identical to natural, plasma-derived factor IX and is widely used in clinical practice. Development of a biosimilar recombinant human factor IX for medical applications requires the generation of a clonal cell line with the highest specific productivity possible and a high level of specific procoagulant activity of the secreted factor IX. We previously developed plasmid vectors, p1.1 and p1.2, based on the untranslated regions of the translation elongation factor 1 alpha gene from Chinese hamster. These vectors allow one to perform the methotrexate- driven amplification o

SUBMITTER: Kovnir SV 

PROVIDER: S-EPMC5916734 | biostudies-literature | 2018 Jan-Mar

REPOSITORIES: biostudies-literature